Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.50 |
| ▸ | EGFR | P00533 | 10/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | FECH | P22830 | 1/20 | 0.50 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.50 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24167297 | 0.91 | ERBB2 (0.53) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167949 | 0.89 | ERBB2 (0.52) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167386 | 0.89 | ERBB2 (0.45) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167239 | 0.88 | ERBB2 (0.62) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167961 | 0.85 | EGFR (0.47) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167899 | 0.85 | EGFR (0.47) | ERBB2EGFRFECH | |
| SCHEMBL24168146 | 0.82 | ERBB2 (0.57) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24569681 | 0.80 | ERBB2 (0.55) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29887861 | 0.80 | ERBB2 (0.55) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26006999 | 0.80 | EGFR (0.47) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | ERBB2 1/4885EGFR 6/4885NQO2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.